Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer. Soon YY, Marschner IC, Schou IM, Sweeney CJ, et al. BJU Int 2025 Nov 5. doi: 10.1111/bju.70065.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Soon YY, Marschner IC, Schou IM, Sweeney CJ, et al. Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer. BJU Int 2025 Nov 5. doi: 10.1111/bju.70065.
PMID: 41190384